Issue Date: May 5, 2014 | Web Date: May 2, 2014
Pfizer Pursues AstraZeneca
Despite two rejections, Pfizer is trying to persuade AstraZeneca to enter talks about a merger. With the clock ticking and negotiations at a standstill, it’s unclear whether Pfizer will switch from persuasion to a hostile takeover as it continues to press its case.
The U.S. firm first approached U.K.-based AstraZeneca about a combination back in November 2013. At a subsequent meeting in January, Pfizer made a preliminary $100 billion offer of . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society